At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 64 target
Drug / intervention
Furmonertinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Single-arm Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression After First-line EGFR-TKI Therapy
In Brief
A Phase 2 clinical trial evaluating Furmonertinib for Non-small Cell Lung Cancer and Oligoprogressive. Targeting 64 participants across 1 site.
Detailed Summary
This Phase II randomized study is to explore the efficacy and safety of Furmonertinib combined with radiotherapy for non-small cell lung cancer with oligoprogression after first-line EGFR-TKI therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer, Oligoprogressive
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20222023202420252026
Enrollment StartJun 2021
First PostedJul 2021
Primary CompletionJan 2024
Study CompletionMay 2024
TodayJul 2026
First PostedJul 21, 2021
Enrollment StartJun 1, 2021
Primary CompletionJan 31, 2024
Study CompletionMay 31, 2024
TodayJul 1, 2026
Enrollment to primary: 2.7 yearsPosted 4.9 years ago
Interventions
Furmonertinibdrug
The different dose of furmonertinib will be given according to the generation of EGFR-TKI used as the first-line therapy. The doses and target volume of radiotherapy will be decided according to the oligoprogressive sites.